Search research articles
Contact Us
Filters
Showing results (481-490 of 643) with videos related to
Page
of 65
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Plos One
|
March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Annals of Translational Medicine
|
June 7, 2019
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts
Guochun Zhang, Yulei Wang, Bo Chen, et al.
RSC Medicinal Chemistry
|
June 11, 2025
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
Ujjwol Khatri, Neetu Dayal, Kofi B Owusu, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 30, 2014
RET fusion as a novel driver of medullary thyroid carcinoma
Elizabeth G Grubbs, Patrick Kwok-Shing Ng, Jacquelin Bui, et al.
Journal of the American Medical Informatics Association : JAMIA
|
September 5, 2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Nathan D Seligson, Jeremy L Warner, William S Dalton, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Journal of the National Cancer Institute
|
February 18, 2015
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer
Ana M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, et al.
Page
of 65
Search research articles
Search
Showing results (481-490 of 643) with videos related to
Sort By:
Page
of 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Plos One
|
March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Annals of Translational Medicine
|
June 7, 2019
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts
Guochun Zhang, Yulei Wang, Bo Chen, et al.
RSC Medicinal Chemistry
|
June 11, 2025
Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
Ujjwol Khatri, Neetu Dayal, Kofi B Owusu, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 30, 2014
RET fusion as a novel driver of medullary thyroid carcinoma
Elizabeth G Grubbs, Patrick Kwok-Shing Ng, Jacquelin Bui, et al.
Journal of the American Medical Informatics Association : JAMIA
|
September 5, 2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Nathan D Seligson, Jeremy L Warner, William S Dalton, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Oncotarget
|
September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Journal of the National Cancer Institute
|
February 18, 2015
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer
Ana M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, et al.
Page
of 65